3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
24
Kidney Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
von Hippel-Lindau Disease
4
Pheochromocytoma
2
Paraganglioma
2
Neoplasm Metastasis
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neoplasms
1
Metastatic Castration-Resistant Prostate Cancer
1
Hemangioblastoma
1
Glioblastoma
1
Endometrial Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma
1
Breast Neoplasms
1
Adenoma, Islet Cell
1
Interventions
Cisplatin
55
Carboplatin
50
pembrolizumab
42
Paclitaxel
42
Gemcitabine
28
Pemetrexed
23
Radiotherapy
21
Magnetic Resonance Spectroscopy
20
Radiotherapy, Intensity-Modulated
18
Docetaxel
17
Cetuximab
17
Specimen Handling
16
Nivolumab
16
Fluorouracil
16
Cyclophosphamide
14
durvalumab
13
Bevacizumab
12
Radiation
11
130-nm albumin-bound paclitaxel
11
Sorafenib
10
Platinum
10
1,2-diaminocyclohexaneplatinum II citrate
10
osimertinib
9
Sunitinib
8
Oxaliplatin
8
Irinotecan
8
Ipilimumab
8
Everolimus
8
Drug Therapy
8
Capecitabine
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma
×
belzutifan
×
Clear all
NCT07227402
2026-06-04
LITESPARK-033
Merck Sharp & Dohme LLC
Phase 3
Recruiting
904 enrolled